REMARKS

Applicants respectfully request entry of the amendments hereinabove, and an early examination and allowance of the claims.

Applicants also claim priority from the applications detailed in the amendment and request acknowledgment of such priority claim.

Claim 1 has been kept as an independent claim for filing purposes and will be cancelled.

An Information Disclosure Statement is enclosed herewith. In compliance with 37 C.F.R. §1.98(d), Applicants are not providing a copy of the references "since they were previously cited by and submitted to the Office in a prior application." The prior application entitled "N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE" had U.S. serial No. 10/096,218 and is the parent of the instant case. In addition, it is relied upon for an earlier filing date under 35 U.S.C. §120.

Please charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this sheet are enclosed.

Respectfully submitted,

Date: October 28 . 2003

A. Dean Olson Reg. No. 31,185 Attorney for Applicant

Pfizer Inc.
Patent Department MS 8260-1611
Eastern Point Road
Groton, CT 06340
Tel.: (860) 441-4904

#64213 v1 - PC10967B PRELIMINARY AMENDMENT